Biogen Inc (BIIB) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Biogen Inc stock (BIIB) is currently trading at $189.18. Biogen Inc PE ratio is 21.50. Biogen Inc PS ratio (Price-to-Sales) is 2.81. Analyst consensus price target for BIIB is $205.90. WallStSmart rates BIIB as Underperform.
- BIIB PE ratio analysis and historical PE chart
- BIIB PS ratio (Price-to-Sales) history and trend
- BIIB intrinsic value — DCF, Graham Number, EPV models
- BIIB stock price prediction 2025 2026 2027 2028 2029 2030
- BIIB fair value vs current price
- BIIB insider transactions and insider buying
- Is BIIB undervalued or overvalued?
- Biogen Inc financial analysis — revenue, earnings, cash flow
- BIIB Piotroski F-Score and Altman Z-Score
- BIIB analyst price target and Smart Rating
Biogen Inc
📊 No data available
Try selecting a different time range
BIIB Intrinsic Value Analysis for Value Investors
Benjamin Graham Formula · Biogen Inc (BIIB)
BIIB trades at a significant discount to its Graham intrinsic value of $330.18, offering a 42% margin of safety — a level value investors typically seek before buying.
Based on Benjamin Graham Formula. Growth rate capped at 25%. For informational purposes only. Not financial advice.
Smart Analysis
Biogen Inc (BIIB) · 10 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in market cap, price/book, institutional own.. Concerns around peg ratio and return on equity. Fundamentals are solid but monitor weak areas for improvement.
Biogen Inc (BIIB) Key Strengths (3)
98.06% of shares held by major funds and institutions
Large-cap company with substantial market presence
Trading at 1.52x book value, attractively priced
Supporting Valuation Data
Biogen Inc (BIIB) Areas to Watch (7)
Revenue declining -7.10%, a shrinking business
Very expensive relative to growth, significant premium
Low profitability relative to shareholder equity
Decent operational efficiency, solid but not exceptional
Revenue is fairly priced at 2.81x sales
Solid earnings growth at 19.20%
Decent profitability, keeps $13 per $100 revenue
Biogen Inc (BIIB) Detailed Analysis Report
Overall Assessment
This company scores 55/100 in our Smart Analysis, earning a C- grade. Out of 10 metrics analyzed, 3 register as strengths (avg 9.0/10) while 7 fall into concern territory (avg 4.1/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Institutional Own., Market Cap, Price/Book. Valuation metrics including Price/Book (1.52) suggest the stock is attractively priced.
The Bear Case
The primary concerns are Revenue Growth, PEG Ratio, Return on Equity. Some valuation metrics including PEG Ratio (3.71), Price/Sales (2.81) suggest expensive pricing. Growth concerns include Revenue Growth at -7.10%, EPS Growth at 19.20%, which may limit upside. Profitability pressure is visible in Return on Equity at 7.39%, Operating Margin at 19.60%, Profit Margin at 13.10%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Revenue Growth improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at 7.39% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at -7.10% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a moderate-to-high risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Mixed fundamentals with both positives (Institutional Own., Market Cap) and negatives (Revenue Growth, PEG Ratio). A cautious approach is warranted. Monitor for improvement in weak areas before increasing conviction.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
BIIB Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
BIIB's Price-to-Sales ratio of 2.81x trades at a deep discount to its historical average of 5.87x (3th percentile). The current valuation is 76% below its historical high of 11.68x set in Feb 2014, and 4% above its historical low of 2.69x in Mar 2026.
Compare BIIB with Competitors
Top DRUG MANUFACTURERS - GENERAL stocks by market cap
Compare any two stocks →WallStSmart Analysis Synopsis
Data-driven financial summary for Biogen Inc (BIIB) · HEALTHCARE › DRUG MANUFACTURERS - GENERAL
The Big Picture
Biogen Inc faces headwinds with declining revenue, though profitability provides a cushion. Revenue reached 9.9B with 7% decline year-over-year. Profit margins of 13.1% are healthy, with room for further expansion as the business scales.
Key Findings
Generating 468M in free cash flow and 512M in operating cash flow. Earnings are translating into actual cash generation.
Revenue contracted 7% YoY. Worth determining whether this is cyclical or structural.
What to Watch Next
Margin expansion: can Biogen Inc push profit margins above 15% as the business scales?
Sector dynamics: monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive moves, and regulatory changes that could impact Biogen Inc.
Bottom Line
Biogen Inc faces challenges with declining revenue. While profitability provides a buffer, the long-term trajectory needs to improve. Watch for management's strategic response and whether the company can stabilize or pivot to new growth drivers.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions(94 last 3 months)
| Insider | Type | Shares |
|---|---|---|
MURPHY, NICOLE Head of Pharm Ops and Tech | Buy | +3 |
| Insider | Type | Shares |
|---|---|---|
SINGHAL, PRIYA Head of Development | Sell | -2,660 |
| Insider | Type | Shares |
|---|---|---|
SINGHAL, PRIYA Head of Development | Sell | -748 |
Data sourced from SEC Form 4 filings
Last updated: 12:56:18 PM
About Biogen Inc(BIIB)
NASDAQ
HEALTHCARE
DRUG MANUFACTURERS - GENERAL
USA
Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, specializing in the discovery, development, and delivery of therapies for the treatment of neurological diseases to patients worldwide.